Genelux (GNLX) Income from Continuing Operations (2022 - 2026)
Genelux (GNLX) posted Income from Continuing Operations of -$9.0 million for Q1 2026, up 3.08% on a QoQ basis from -$9.3 million in Q4 2025, and down 17.9% year-over-year from -$11.0 million in Q1 2025.
Analysis
Genelux (GNLX) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Genelux has reported Income from Continuing Operations for 5 years, with the latest figure at -$9.0 million in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 17.9% year-over-year to -$9.0 million in Q1 2026; TTM through Mar 2026 was -$33.9 million, a 10.59% decrease from a year earlier, with the FY2025 full-year figure at -$32.5 million, down 4.86% from the prior year.
- Income from Continuing Operations was -$9.0 million for Q1 2026 at Genelux, up from -$9.3 million in the prior quarter.
- The five-year high for Income from Continuing Operations was $4.9 million in Q3 2022, with the low at -$9.6 million in Q1 2023.
- Average Income from Continuing Operations over 5 years is -$6.5 million, with a median of -$7.6 million recorded in 2025.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations tumbled 208.88% in 2023, then rose 17.99% in 2024.
- Over 5 years, Income from Continuing Operations stood at -$3.5 million in 2022, then slumped by 93.62% to -$6.8 million in 2023, then slumped by 41.08% to -$9.5 million in 2024, then rose by 2.75% to -$9.3 million in 2025, then advanced by 3.08% to -$9.0 million in 2026.
- The last three Income from Continuing Operations figures came in at -$9.0 million (Q1 2026), -$9.3 million (Q4 2025), and -$8.0 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 601.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Genelux | 108.17 Mn | 108.17 Mn | - | -9.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -9.00 Mn |
| Dec 31, 2025 | -9.28 Mn |
| Sep 30, 2025 | -8.02 Mn |
| Jun 30, 2025 | -7.57 Mn |
| Mar 31, 2025 | -7.63 Mn |
| Dec 31, 2024 | -9.55 Mn |
| Sep 30, 2024 | -6.72 Mn |
| Jun 30, 2024 | -6.73 Mn |
| Mar 31, 2024 | -7.85 Mn |
| Dec 31, 2023 | -6.77 Mn |
| Sep 30, 2023 | -5.35 Mn |
| Jun 30, 2023 | -5.42 Mn |
| Mar 31, 2023 | -9.57 Mn |
| Dec 31, 2022 | -3.50 Mn |
| Sep 30, 2022 | 4.91 Mn |